T5155-10
Clone Type
MonoclonalHost
MouseSource
HumanIsotype
IgG1,kClone Number
TS106 (0.N.569)Grade
Affinity PurifiedApplications
E FC IF IP WBCrossreactivity
HuShipping Temp
Blue IceStorage Temp
-20°CMouse Anti-Thymidylate Synthase (TS)
Thymidylate Synthase (TS)1 (EC 2.1.1.45) converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. TS is a critical target for the fluoropyrimidines, an important group of antineoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates TS by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of TS protein is associated with response to 5-fluorouracil (5-FU) in human colorectal,4,5 gastric,5 head and neck,6 and breast7 carcinomas.
Applications
Suitable for use in ELISA, Flow Cytometry, Immunofluorescence, Immunoprecipitation and Western Blot. Not suitable for use in Immunohistochemistry. Other applications have not been tested.
Recommended Dilution
Immunoprecipitation (Native verified) (Use Protein G): 2ug/mg protein lysate Western Blot: 1-2ug/ml for 2hrs at RT Optimal dilutions to be determined by the researcher.
Positive Control
5-FU-resistant cell cancer lines or colon carcinoma.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Recombinant human TS enzyme (36kD). Cellular Localization: Nuclear and cytoplasmic
Form
Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.1% sodium azide. Also available without BSA and azide. See T5155-10X.
Purity
Purified by Protein G affinity chromatography.
Specificity
Recognizes human Thymidylate Synthase
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Johnston PG, et. al. Cancer Res, 1991, 51(24):6668–76. 2. Johnston PG, et. al. Cancer Res, 1992, 52(16):4306–12. 3. Johnston PG, et. al. Biochem Pharmac, 1993, 45:2483–6. 4. Johnston PG, et. al. J Clin Oncol, 1994, 12(12):2640–7. 5. Johnston PG, et. al. Cancer Res, 1995, 55(7):1407–12. 6. Johnston PG, et. al. J Natl Cancer Inst, 1997, 89(4):308–13. 7. Pestalozzi BC, et. al. J Clin Oncol, 1997, 15(5):1923–31.USBio References
No references available